<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428454</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2006-02</org_study_id>
    <nct_id>NCT00428454</nct_id>
  </id_info>
  <brief_title>Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions</brief_title>
  <official_title>A Randomized Comparison of Sirolimus-eluting Stent Implantation With Zotarolimus-eluting Stent Implantation for the Treatment of Chronic Total Coronary Occlusions. The PRISON III Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R&amp;D Cardiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <brief_summary>
    <textblock>
      Primary intracoronary stent placement after successfully crossing chronic total coronary
      occlusions (CTO) decreases the high restenosis rate at long-term follow-up compared with
      conventional balloon angioplasty. Several studies have shown the efficacy of
      sirolimus-eluting stents in selected groups of patients. In the PRISON II study we
      demonstrated that sirolimus-eluting stents were superior to bare metal stents in CTO. In this
      prospective randomized trial, sirolimus-stent implantation will be compared with
      zotarolimus-eluting stent implantation for the treatment of chronic total coronary
      occlusions. A total of 300 patients will be clinically followed up for 1, 6, 12 months, 2, 3,
      4, 5 year with angiographic follow-up at 8 months. Quantitative coronary analysis will be
      performed by an independent core laboratory. The primary end point is in-segment late luminal
      loss at 8 month angiographic follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) was traditionally
      limited by high restenosis rates. Coronary stenting using bare metal stents significantly
      decreases restenosis in CTO compared to balloon angioplasty alone, but restenosis rates still
      reach 32-55%. In 200 patients with CTO, randomized in the PRISON I study we demonstrated a
      restenosis rate of 22% after bare metal stent (BMS) implantation as compared with 33% after
      conventional balloon angioplasty. During the past few years, sirolimus (rapamycin), a
      cytostatic macrocyclic lactone with anti-inflammatory and antiproliferative properties,
      delivered from a polymer-encapsulated stent was shown to almost eliminate the risk of
      restenosis in selected groups of patients. The drug zotarolimus (ABT-578), a sirolimus
      analogue, is designed to inhibit the cellular process that leads to restenosis. In the PRISON
      II study we have randomized 200 patients with CTO to either BMS implantation or
      sirolimus-eluting stent implantation and we demonstrated a reduction of in-stent binary
      restenosis from 36% to 7% and in-segment binary restenosis rates from 41% to 11% in favour of
      the sirolimus eluting stent. However, no data are available on direct comparison of the
      clinical efficacy, safety, and angiographic outcome of particular drug-eluting stents in
      patients with CTO and there may be differences between various drug-eluting stents. The
      PRISON III study is designed to address this issue and provide information about two
      different drug-eluting stents. It is a prospective randomized, single blinded trial comparing
      the relative safety, clinical efficacy and angiographic outcomes of sirolimus and
      zotarolimus-eluting stents in patients undergoing successful recanalization of CTO.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss at 8 months as assessed by an independent angiographic core lab.</measure>
    <time_frame>8 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent late luminal loss</measure>
    <time_frame>8 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment binary restenosis rate</measure>
    <time_frame>8 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment MLD</measure>
    <time_frame>8 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage diameter stenosis</measure>
    <time_frame>8 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A composite of major adverse cardiac events (MACE: death, myocardial infarction and clinically driven target lesion revascularization)</measure>
    <time_frame>8 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (acute, &lt;1day; subacute, 1 to 30 days; and late, &gt;30 days)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure up to 5 year of clinical follow-up.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Zotarolimus eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zotarolimus eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-eluting stent, zotarolimus-eluting stent</intervention_name>
    <description>PCI in chronically occluded coronary artery</description>
    <arm_group_label>Zotarolimus eluting stent</arm_group_label>
    <arm_group_label>Sirolimus eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  the estimated duration of the occlusion is at least 2 weeks.

          -  signs of ischemia related to the occluded coronary artery.

          -  successful recanalization of the occluded artery is achieved.

          -  reference diameter is &gt; 2.5 mm.

          -  written informed consent obtained.

        EXCLUSION CRITERIA

          -  primary or rescue PCI for acute myocardial infarction

          -  the lesion could not be crossed.

          -  lesions with complex anatomy making successful stent deployment unlikely.

          -  the guide wire is not in the true lumen distal to the occlusion.

          -  Sirolimus or zotarolimus allergy

          -  venous or arterial bypass grafts

          -  pregnant or nursing women.

          -  participation in an other trial.

          -  factors making long-term follow-up difficult or unlikely.

          -  life expectancy &lt;1 year.

          -  contraindications for ASA or Clopidogrel or heparin.

          -  use of coumadins that could not be stopped before the procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten J. Suttorp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rahel BM, Suttorp MJ, Laarman GJ, Kiemeneij F, Bal ET, Rensing BJ, Ernst SM, ten Berg JM, Kelder JC, Plokker HW. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J. 2004 May;147(5):e22.</citation>
    <PMID>15131557</PMID>
  </reference>
  <reference>
    <citation>Suttorp MJ, Mast EG, Plokker HW, Kelder JC, Ernst SM, Bal ET. Primary coronary stenting after successful balloon angioplasty of chronic total occlusions: a single-center experience. Am Heart J. 1998 Feb;135(2 Pt 1):318-22.</citation>
    <PMID>9489982</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994 Aug 25;331(8):489-95.</citation>
    <PMID>8041413</PMID>
  </reference>
  <reference>
    <citation>Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994 Aug 25;331(8):496-501.</citation>
    <PMID>8041414</PMID>
  </reference>
  <reference>
    <citation>Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.</citation>
    <PMID>14523139</PMID>
  </reference>
  <reference>
    <citation>Sirnes PA, Golf S, Myreng Y, Mølstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996 Nov 15;28(6):1444-51.</citation>
    <PMID>8917256</PMID>
  </reference>
  <reference>
    <citation>Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006 Aug 29;114(9):921-8. Epub 2006 Aug 14.</citation>
    <PMID>16908768</PMID>
  </reference>
  <reference>
    <citation>Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. Epub 2006 Nov 28.</citation>
    <PMID>17174180</PMID>
  </reference>
  <reference>
    <citation>Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. Epub 2006 Aug 14.</citation>
    <PMID>16908773</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>R&amp;D Cardiologie</investigator_affiliation>
    <investigator_full_name>Dr. M.J. Suttorp</investigator_full_name>
    <investigator_title>MD, PhD, FESC, FACC</investigator_title>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>chronic total occlusion</keyword>
  <keyword>sirolimus-eluting stent</keyword>
  <keyword>zotarolimus-eluting stent</keyword>
  <keyword>QCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

